Intermittent Fasting in Nonalcoholic Fatty Liver Disease
- Conditions
- Insulin ResistanceNon-Alcoholic Fatty Liver DiseaseIntermittent FastingObesityGut Microbiota
- Interventions
- Behavioral: Calorie restriction
- Registration Number
- NCT04355910
- Lead Sponsor
- Shaoguan University
- Brief Summary
Although preliminary evidence suggests that intermittent fasting mimic-diet (IFD) exerts stronger effects on body weight and metabolic parameters, which may link obesity, non-alcoholic fatty liver disease (NAFLD) and major chronic diseases, compared with continuous calorie restriction (CCR), there is a lack of well-powered intervention studies. This randomized controlled trial will test whether IFD, operationalized as the "5:2 diet," has stronger effects on anthropometric and body composition characteristics, and circulating metabolic biomarkers than CCR and a control regimen in adults with NAFLD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 120
- The diagnosed criteria of fatty liver by ultrasound were presence of two of the three following criteria: increased hepatic echogenicity compared with cortical of the right kidney, blurring of liver vasculature, and deep attenuation of the ultrasonographic signal.
- Excessive alcohol consumption (ethanol > 140 g/wk for men and > 70 g/wk for women), cirrhosis, viral hepatitis, cardiovascular disease, cancer, any consumption of nonsteroidal anti-inflammatory drugs, corticosteroids or prescriptive medicine that affect liver function, lipid and glucose metabolism.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Intermittent fasting mimic-diet (IFD) Calorie restriction Restrict 75% energy on two non-consecutive days each week. Continuous calorie restriction (CCR) Calorie restriction A daily 25% energy-restricted Mediterranean-type diet
- Primary Outcome Measures
Name Time Method Body weight Change from baseline body weight at week 8 Change of body weight
- Secondary Outcome Measures
Name Time Method Gut microbiota Change from baseline plasma bile acids and the gut microbiome at week 8 Changes of blood metabolites and the gut microbiome
Lipid profile Change from baseline plasma TG, TC and LDL at week 8 Plasma lipids levels
Insulin resistance Change from baseline plasma glucose and insulin at week 8 Plasma glucose and insulin levels
Trial Locations
- Locations (1)
Guangdong Medical University
🇨🇳Dongguan, Guangdong, China